MedTrace Logo

Use of Ziv Aflibercept in Different Retinal Diseases

NCT04290195 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-10-11

No results posted yet for this study

Summary

A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.

Conditions

  • Central Retinal Vein Occlusion With Macular Edema

Interventions

DRUG

Ziv-Aflibercept 25 MG/ML [Zaltrap]

Intravitreal injection of 1.25 mg of ziv aflibercept in patients

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Amin El Sayed Nawar

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
31 Years
Max Age
63 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2019-12-01
Completion
2020-01-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04290195 on ClinicalTrials.gov